Researchers have developed a way to use ultrasound to predict whether a pregnant person is at risk of delivering a baby prematurely, which occurs in upward of 10% of pregnancies in the U.S.
Roche wins first approval for subcutaneous Tecentriq – Pharmaceutical Technology
Tecentriq is Roche’s second highest-grossing oncology drug, generating SFr1.8bn ($2.1bn) in H1 2023. Image Credit: Judith Linine / Shutterstock. Roche has beaten competitors to score
August 30, 2023